Stable Istotope Labelled Olaratumab Biosimilar – Anti-PDGF-R alpha mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Istotope Labelled Olaratumab Biosimilar - Anti-PDGF-R alpha mAb - Research Grade |
|---|---|
| Source | DrugBank DB06043 |
| Species | Human |
| Expression system | Mammalian cells |
| Molecular weight | 154kDa |
| Purity | >95% |
| Buffer | PBS pH7.5 |
| Delivery condition | Blue Ice |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | 4°C for short term; -20°C for long term |
| Brand | ProteoGenix |
| Aliases /Synonyms | Olaratumab |
| Reference | PX-TA1025-SIL |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1Kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
| Formula | C6554H10076N1736O2048S40 |
General information about Olaratumab
Olaratumab is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-? with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. This product is for research use only.
Contact us
Send us a message from the form below
Reviews
There are no reviews yet.